PARK7
Basics
Aliases:
This biomarker is also known as:- Parkinson disease (autosomal recessive, early onset) 7,
- Parkinson disease protein 7,
- Oncogene DJ-1,
- Protein DJ-1,
- DJ1,
- DJ-1,
Description…
DJ-1, also known as PARK-7, belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death. DJ-1 is highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart and is detected at slightly lower levels in placenta and brain.
Attributes
| QA State: | Accepted |
|---|---|
| Type: | Protein |
| Short Name: |
Datasets
There are no datasets associated with this biomarker.
Organs
The following organs have data associated with this biomarker…
Lung
Attributes
| Phase: | Three |
|---|---|
| QA State: | Under Review |
Overview
Validation study was conducted to determine whether DJ-1 antigens are associated with autoantibodies in sera collected at the pre-symptomatic stage of lung cancer.
Performance Comment
Supporting Study Data
The following studies/protocols provide evidence supporting PARK7 indications for the Lung…
Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques
1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
View more about this studyBiomarker Characteristics Summary
| Notes | Sensitivity | Specificity | Prevalence | NPV | PPV | Specific Assay Type |
|---|---|---|---|---|---|---|
| Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. | 39.0 | 51.0 | 0.0 | |||
| Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. | 82.0 | 25.0 | 0.0 |
Decision Rule
No extra decision rule information available
Additional Study-Specific Protocols
Study-Specific Publications
- Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera.
Study-Specific Resources
No study-specific resources defined.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Studies
No associated studies or protocols found.
